X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ascidian will provide Roche exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets and will conduct discovery and preclinical activities.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,842.0 million Upfront Cash: $42.0 million
Deal Type: Collaboration June 18, 2024
Details:
ACDN-01 is the first-ever clinical-stage RNA exon editor, which is being evaluated in preclinical studies for the treatment of Stargardt disease & ABCA4 retinopathies.
Lead Product(s): ACDN-01
Therapeutic Area: Genetic Disease Product Name: ACDN-01
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
The funds will be used to advance Ascidian's lead program, an RNA exon editor to halt the progression of Stargardt disease or other ABCA4 retinopathies, and additional programs in the company's pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Apple Tree Partners
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 08, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
